299 related articles for article (PubMed ID: 2513368)
1. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens.
Mosley ST; Kalinowski SS; Schafer BL; Tanaka RD
J Lipid Res; 1989 Sep; 30(9):1411-20. PubMed ID: 2513368
[TBL] [Abstract][Full Text] [Related]
2. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Koga T; Shimada Y; Kuroda M; Tsujita Y; Hasegawa K; Yamazaki M
Biochim Biophys Acta; 1990 Jul; 1045(2):115-20. PubMed ID: 2116173
[TBL] [Abstract][Full Text] [Related]
3. Effects of long-term administration of HMG-CoA reductase inhibitors on cholesterol synthesis in lens.
Kalinowski SS; Tanaka RD; Mosley ST
Exp Eye Res; 1991 Aug; 53(2):179-86. PubMed ID: 1915674
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors.
Parker RA; Clark RW; Sit SY; Lanier TL; Grosso RA; Wright JJ
J Lipid Res; 1990 Jul; 31(7):1271-82. PubMed ID: 2401858
[TBL] [Abstract][Full Text] [Related]
5. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes.
Masters BA; Palmoski MJ; Flint OP; Gregg RE; Wang-Iverson D; Durham SK
Toxicol Appl Pharmacol; 1995 Mar; 131(1):163-74. PubMed ID: 7878672
[TBL] [Abstract][Full Text] [Related]
6. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
[TBL] [Abstract][Full Text] [Related]
7. Cholesterol content of the rat lens is lowered by administration of simvastatin, but not by pravastatin.
De Vries AC; Vermeer MA; Bredman JJ; Bär PR; Cohen LH
Exp Eye Res; 1993 Apr; 56(4):393-9. PubMed ID: 8500554
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
9. Pravastatin and simvastatin differently inhibit cholesterol biosynthesis in human lens.
de Vries AC; Vermeer MA; Bloemendal H; Cohen LH
Invest Ophthalmol Vis Sci; 1993 Feb; 34(2):377-84. PubMed ID: 8440592
[TBL] [Abstract][Full Text] [Related]
10. Hypercholesterolaemia: simvastatin and pravastatin alter cholesterol metabolism by different mechanisms.
Owens D; Collins P; Johnson A; Tighe O; Robinson K; Tomkin GH
Biochim Biophys Acta; 1991 Apr; 1082(3):303-9. PubMed ID: 1903069
[TBL] [Abstract][Full Text] [Related]
11. Tissue-selective inhibition of sterol synthesis in mice by pravastatin sodium after a single or repeated oral administrations.
Koga T; Kikuchi T; Miyazaki A; Koike H
Lipids; 1995 Aug; 30(8):775-9. PubMed ID: 7475995
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of rat brain prostaglandin D synthase by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Islam F; Watanabe Y; Hayaishi O
Biochem Int; 1990 Nov; 22(4):601-5. PubMed ID: 2127671
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cholesterol synthesis and hepatic 3-hydroxy-3-methylglutaryl--CoA reductase in rats by simvastatin and pravastatin.
Del Puppo M; Rauli S; Galli Kienle M
Lipids; 1995 Nov; 30(11):1057-61. PubMed ID: 8569435
[TBL] [Abstract][Full Text] [Related]
14. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin.
Serajuddin AT; Ranadive SA; Mahoney EM
J Pharm Sci; 1991 Sep; 80(9):830-4. PubMed ID: 1800703
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology and mechanism of action of the new HMG-CoA reductase inhibitors.
Sirtori CR
Pharmacol Res; 1990; 22(5):555-63. PubMed ID: 2126139
[TBL] [Abstract][Full Text] [Related]
16. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro.
Kurakata S; Kada M; Shimada Y; Komai T; Nomoto K
Immunopharmacology; 1996 Aug; 34(1):51-61. PubMed ID: 8880225
[TBL] [Abstract][Full Text] [Related]
17. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors.
Bocan TM; Ferguson E; McNally W; Uhlendorf PD; Bak Mueller S; Dehart P; Sliskovic DR; Roth BD; Krause BR; Newton RS
Biochim Biophys Acta; 1992 Jan; 1123(2):133-44. PubMed ID: 1739744
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M
Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Aoki T; Nishimura H; Nakagawa S; Kojima J; Suzuki H; Tamaki T; Wada Y; Yokoo N; Sato F; Kimata H; Kitahara M; Toyoda K; Sakashita M; Saito Y
Arzneimittelforschung; 1997 Aug; 47(8):904-9. PubMed ID: 9296275
[TBL] [Abstract][Full Text] [Related]
20. Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.
Qin W; Infante J; Wang SR; Infante R
Biochim Biophys Acta; 1992 Jul; 1127(1):57-66. PubMed ID: 1627634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
